PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION's lead compound, Remimazolam, is an ultra-short-acting intravenous sedative and anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. 

PAION's Remimazolam

news

02/09/2016

Press Release: PAION discontinues European Remimazolam Phase III Trial in...

PAION discontinues European Remimazolam Phase III Trial in...

Read more
02/09/2016

Ad hoc release: PAION discontinues European Remimazolam Phase III Trial in...

PAION discontinues European Remimazolam Phase III Trial in...

Read more
12/01/2015

PAION announces initiation of U.S. clinical safety trial of Remimazolam in high...

PAION announces initiation of U.S. clinical safety trial of...

Read more

PAION Chart